Current Report · Items 5.02 · 8-K
Tecogen Inc.
TGENNYSE_AMERICANEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02. Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers. On June 26, 2026, the Compensation Committee of Tecogen Inc.…
Company context
Current securities
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers.
On June 26, 2026, the Compensation Committee of Tecogen Inc. (the “Company”) recommended to the Company’s Board of Directors that in order to align the economic interests of the Company’s Chief Executive Officer, Abinand Rangesh, and its other named executive officers with the interests of the Company and its stockholders, the Company grant to them the following awards of restricted stock and incentive stock options pursuant to the Company’s 2022 Stock Incentive Plan. The Company’s Board of Directors approved such awards at a meeting held on June 26, 2026.
Named Executive Officer Equity Grant Number of Shares of Restricted Stock or Shares Underlying Options
───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
Abinand Rangesh, CEO Restricted Stock Award 174,081
Incentive Stock Option 26,041
Robert A. Panora, President and COO Restricted Stock Award 9,671
Incentive Stock Option 26,041
Roger Deschenes, CFO Restricted Stock Award 29,013
Stephen Lafaille, VP of Business Development Restricted Stock Award 29,013
John K. Whiting, IV, General Counsel & Secretary Restricted Stock Award 19,342
Each of such awards vests in equal installments on the first, second, third, and fourth anniversaries of the date of grant. The incentive stock options are exercisable at a price of $5.17 per share.
In addition, the Compensation Committee also recommended to the Board, and the Board approved at the above referenced meeting, increases in the cash compensation payable to Mr. Rangesh and each named executive officer. Mr. Rangesh’s annual base salary was increased by 5% to $220,500; and each named executive officer’s base salary was increased by 3% as follows: Mr. Panora’s annual base salary was increased to $206,000; Mr. Deschenes’ annual base salary was increased to $185,400; Mr. Lafaille’s annual base salary was increased to $152,260; and Mr. Whiting’s annual base salary was increased to $185,400.